1349 ET - Corvus Pharmaceuticals plunges 40% following interim data from a Phase 1 clinical trial of its eczema treatment. CEO Richard Miller says the company is pleased with the early results of its soquelitinib treatment. Investors, though, appear unsold. Oppenheimer analyst Jeff Jones says the drop might be a "buy the rumor, sell the news," reaction since shares were up nearly 300% year-to-date. Or investors might've been expecting data from both cohort 1 and 2 and were disappointed that only cohort 1 data was released, he adds. (connor.hart@wsj.com)
(END) Dow Jones Newswires
December 18, 2024 13:49 ET (18:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.